Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

LYRA vs AVTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVTX Captures Overall Composite Edge (49.6 HOLD vs 52.2 HOLD), While LYRA Leads 3–2 on Growth & Valuation Pillars

AVTX Overall Winner 6-Pillar Tally: LYRA 3 – 2 AVTX (1 Tie) Matrix Metrics: LYRA 2 – 5 AVTX

As of Nov 17, 2026, Avalo Therapeutics, Inc. (AVTX) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (49.6/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Balance Sheet & Cash Flow), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. LYRA trades at $0.49 (N/M Forward P/E, -25032.0% operating margin) versus AVTX at $7.04 (N/M Forward P/E, -161962.7% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. AVTX 49.6/100 HOLD), AVTX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-161962.7% vs. -25032.0% operating margin) and revenue trajectory (-69.3% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LYRA vs AVTX
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82
AVTX NASDAQ Head-to-Head Winner
Avalo Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$7.04
-4.48% 1D
Market Cap $448.7M
TTM Revenue $59,000
Forward P/E N/M
Beta / 30D Vol 1.74β · 164% Vol
Unified Composite Score
49.6 / 100 HOLD
Tech 69.0 Fund 65.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.1%), weak momentum, RSI 34
RSI-14: 33.8 · SMA20: $7.49 · SMA50: $11.83

6-Pillar Scorecard Institutional Category Breakdown (LYRA 3 – 2 AVTX)

Columns: Metric · LYRA · AVTX
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.9x N/M
2. Growth & Scale AVTX
Revenue Growth (YoY) -87.2% -69.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $600,000 $59,000
Market Cap $2.3M $448.7M
3. Profitability & Quality LYRA
Gross Margin N/A N/A
Operating Margin -25032.0% -161962.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -404.5% -33.6%
4. Balance Sheet & Cash Flow AVTX
Cash Generation (TTM) -$32M EBITDA -$63M
Cash Flow Margin N/A N/A
Net Cash / Leverage -404.5% ROE $65M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LYRA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 114.2% (22nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LYRA (2) vs AVTX (5)
Institutional Metric LYRA AVTX Criterion Row Edge
Market Capitalization
Scale
$2.3M $448.7M Larger Scale AVTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-87.2% -69.3% Higher Growth AVTX
Operating Margin (TTM)
Profitability
-25032.0% -161962.7% Higher Margin LYRA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-404.5% -33.6% Higher ROE AVTX
52-Week Range Position
Momentum
1% ($0–$38) 3% ($7–$24) Stronger Trend AVTX
Beta / 30D Volatility
Risk Regime
0.33β · 248% Vol 1.74β · 164% Vol Lower Realized Risk AVTX
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 49.6 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
$600,000 $59,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M EBITDA (-404.5% ROE) -$63M ($65M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVTX +73.75 pp
LYRA: -62.5% · AVTX: +11.25%
3M Horizon AVTX +69.73 pp
LYRA: -87.62% · AVTX: -17.89%
6M Horizon AVTX +93.16 pp
LYRA: -87.14% · AVTX: +6.02%
1Y Horizon AVTX +93.16 pp
LYRA: -87.14% · AVTX: +6.02%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LYRA Revenue AVTX Revenue LYRA Op. Margin AVTX Op. Margin Margin Leader
FY2018 N/A $10M N/A -503.4% AVTX
FY2019 N/A $10M N/A -239.1% AVTX
FY2020 N/A $10M N/A -1087.4% AVTX
FY2021 $0M $10M -15303.5% -1521.6% AVTX
FY2022 $0M $20M -4131.0% -207.4% AVTX
FY2023 $0M $0M -4308.1% -1421.6% AVTX
FY2024 $0M $0M -6280.8% -15535.6% LYRA
FY2025 $0M $0M -7794.5% -123601.7% LYRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVTX BREAKDOWN
134d in phase · OBV DISTRIBUTION
Current IV 114.2%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $448.7M market capitalization and -161962.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LYRA vs AVTX Key Questions & Quantitative Answers

As of Nov 17, 2026, Avalo Therapeutics, Inc. (AVTX) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (49.6/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Balance Sheet & Cash Flow), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. LYRA trades at $0.49 (N/M Forward P/E, -25032.0% operating margin) versus AVTX at $7.04 (N/M Forward P/E, -161962.7% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. AVTX 49.6/100 HOLD), AVTX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-161962.7% vs. -25032.0% operating margin) and revenue trajectory (-69.3% vs. -87.2% YoY). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVTX leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with AVTX at -69.3% YoY revenue growth and +0.0% YoY earnings growth on $59,000 TTM revenue (N/A gross margin, -161962.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LYRA cumulative revenue shifted N/A while AVTX shifted +100.0%. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVTX.

LYRA screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas AVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus AVTX (-33.6% ROE) capital efficiency.

In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, AVTX carries 114.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 164% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.